| |
|
Headlines:
|
 |
Acute myeloid leukemia
Symptoms and signs
Updated: October 27, 2005
AML is usually diagnosed in adults after a few days of nonspecific
symptoms which are due to abnormal blood cell number, such as fatigue,
weakness, bruises, small rash-like spots, gum and nose bleeds or
infection. In some patients, particularly younger ones, present with
acute symptoms over a few days to 1-2 weeks. Others have a longer
course, with fatigue or other symptoms lasting from weeks to months.
A longer course may suggest an antecedent hematologic disorder such
as MDS.
Generally speaking, manifestations result from either
bone marrow failure, organ infiltration with leukemic cells or both.
Effects on hematopoeisis
Most of the symptoms associated with AML (such as fatigue,
weakness, bruises, small rash-like spots, gum and nose bleeds or
infection) are all reflections of the anemia, thrombocytopenia, and
decrease in functional neutrophils associated with marrow
replacement by malignant cells.
So, whereas, classically elevated WBCs are expected in leukemia
this only happens in about 10% of the patients and constitutes a bad
prognostic sign as they are at increased risk of CNS disease, tumor
lysis syndrome, and leukostasis due to impedance of blood flow from
intravascular clumping of blasts, which are “stickier” than mature
myeloid cells. More commonly patients present with pancytopenia and
a decrease in WBCs as a result of a decrease in functional
neutrophils associated with marrow replacement by malignant cells.
Physical findings
Physical findings in AML are usually minimal.
- Pallor (anemia).
- Increased ecchymoses or petechiae, retinal hemorrhage
(thrombocytopenia, coagulopathy).
- Fever may occur due to infection (leukopenia).
- Signs relating to leukostasis include respiratory distress
and altered mental status (leukocytosis).
- Patients with a high leukemic cell burden may present with
bone pain caused by increased pressure in the bone marrow.
-
Manifestations of organ infiltration include:
Gingival hypertrophy, and cutaneous involvement (leukemia
cutis). Visceral involvement (hepatosplenomegaly and, to a
lesser degree, lymphadenopathy) is also rare, occurring as an
initial manifestation of AML in < 5% of cases, but it may be
more frequent during subsequent relapses.
These focal collections of blasts, called chloromas or
granulocytic sarcomas, can present as soft-tissue masses,
infiltrative lesions of the small bowel and mesentery, or
obstructing lesions of the hepatobiliary or genitourinary
system. Organ inflitration is generally more common with
monocytic (M4 or M5) variants of AML than with other variants of
AML.

|
|
|
|
Are you a doctor or a nurse?
Do you want to join the Doctors Lounge online medical community?
Participate in editorial activities (publish, peer review, edit) and
give a helping hand to the largest online community of patients.
Click on the link below to see the requirements:
Doctors Lounge Membership
Application |
|
Hyperuricemia
Hyperuricemia with possible interstitial or ureteral obstruction
is seen predominantly in AML with moderate leukocytosis; this
condition may be exacerbated by a rapid response to chemotherapy and
the “tumor lysis syndrome” (hyperuricemia with renal insufficiency,
acidosis, hyperphosphatemia, and hypocalcemia), which may occur
within the first 24-48 hours after initiating chemotherapy. To
prevent this complication, all patients should receive allopurinol
(Zyloprim) and urine alkalinization before marrow-ablative
chemotherapy is initiated.
Coagulopathies
Coagulopathies can also complicate the hemostatic defects
associated with thrombocytopenia. Disseminated intravascular
coagulation (DIC) is most often seen in APL (French-American-British
Cooperative group [FAB] subtype M3) due to release of procoagulants
from the abnormal primary granules, which activate the coagulation
cascade, leading to decreased factors II, V, VIII, and X, and
fibrinogen, as well as rapid platelet consumption. Lysozyme released
from monoblasts in M4 and M5 subtypes of AML can also trigger the
clotting cascade.
|
|